CEO Buys 1M Shares, Boosting Confidence as CMT Acquires BioDefense
CEO Warbington’s fresh $1.03 share buy signals confidence in CMT’s stem‑cell and BioDefense immunotherapy merger—potential high‑reward growth amid volatility.
3 minutes to read
CREATIVE MEDICAL TECHNOLOGY